title: Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
abstract: The value of intratumoral thymidylate synthase (TS) quantitation as a predictive parameter for hepatic artery infusion (HAI) chemotherapy in patients with colorectal liver metastases was investigated. Relative TS mRNA levels were determined in 29 tumor samples using a quantitative RT-PCR amplification method. The median level of expression was 3.0 x 10(-3) (no units) and varied considerably among the tumors over a range of 135-fold. Patients with low TS levels were 4.1-fold more likely to respond (P < 0.03) compared to patients with high TS levels. Our results indicate that TS quantitation is a valuable predictive marker for tumor response to HAI therapy.
authors.affiliation: Department of General Surgery, University of Ulm, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kornmann
authors.forename: K H
authors.initials: KH
authors.lastname: Link
authors.forename: H J
authors.initials: HJ
authors.lastname: Lenz
authors.forename: J
authors.initials: J
authors.lastname: Pillasch
authors.forename: R
authors.initials: R
authors.lastname: Metzger
authors.forename: U
authors.initials: U
authors.lastname: Butzer
authors.forename: G H
authors.initials: GH
authors.lastname: Leder
authors.forename: M
authors.initials: M
authors.lastname: Weindel
authors.forename: F
authors.initials: F
authors.lastname: Safi
authors.forename: K D
authors.initials: KD
authors.lastname: Danenberg
authors.forename: H G
authors.initials: HG
authors.lastname: Beger
authors.forename: P V
authors.initials: PV
authors.lastname: Danenberg
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D016133:Polymerase Chain Reaction / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000032:analysis / Q000096:biosynthesis*; D014158:Transcription, Genetic
chemical_list: D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; D012333:RNA, Messenger; D005467:Floxuridine; D015251:Epirubicin; D008942:Mitoxantrone; D013940:Thymidylate Synthase; D002955:Leucovorin; D005472:Fluorouracil